![]() ![]() Therefore, it is relevant to accurately distinguish tumours with an immunohistochemistry score 1+ from those scored 0. ![]() The author emphasizes that it becomes clinically important to distinguish truly HER2 negative from HER2 low breast cancer as treatment options are becoming available. This E-Learning module underlines the fact that the dichotomous view of HER2 status, being either positive or negative, has come to an end. ESMO Recommendations in Precision Medicine.Precision Medicine and Validated Biomarkers.Multikinase Inhibitor-Related Skin Toxicity.Cancer in Special situations (pregnancy, young, elderly, hereditary.).Cancer Aetiology, Epidemiology and Prevention.PARP inhibition and DNA Damage Response (DDR).Drug-Drug Interactions with Kinase Inhibitors.Anti-Cancer Agents and Biological Therapy.Hasenclever-Index for Hodgkin's Disease.International Prognostic Index Tools for Lymphoma.ESMO Webinar Series on-demand recordings.Clinical Pharmacology of Anti-Cancer Agents.Cancer Treatment in Special Clinical Situations.Rehabilitation Issues During Cancer Treatment and Follow-Up.Cancer Diagnosis and Treatment Evaluation.Interpreting Oncological Study Publications.
0 Comments
Leave a Reply. |